Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 (SPRINTER)
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
Sponsor: Synairgen Research Ltd.
Listed as NCT04732949, this PHASE3 trial focuses on COVID-19 and Severe Acute Respiratory Syndrome Coronavirus 2 and remains completed. Sponsored by Synairgen Research Ltd., it has been updated 12 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Study Description(click to expand)Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule.
Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Apr 2022 — Apr 2023 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Dec 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Synairgen Research Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Almada, Portugal , Amarillo, United States , Angers, France , Ashdod, Israel , Aurangabad, India , Bangalore, India , Barcelona, Spain , Barranquilla, Colombia , Belgrade, Serbia and 89 more locations